Charles K. Dargan - Mar 22, 2022 Form 4 Insider Report for BIOLARGO, INC. (BLGO)

Role
Chief Financial Officer
Signature
/s/ John R. Browning, Attorney-in-fact
Stock symbol
BLGO
Transactions as of
Mar 22, 2022
Transactions value $
$0
Form type
4
Date filed
3/28/2022, 09:27 PM
Previous filing
May 24, 2021
Next filing
Apr 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLGO Option to purchase common stock Award +300K +8.2% 3.96M Mar 22, 2022 Common stock 300K $0.24 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Option is exercisable according to its vesting schedule: (i) 25,000 shares vested as of March 22, 2022, and then (ii) in equal monthly installments of 25,000 shares beginning March 31, 2022, so long as the Engagement Extension Agreement dated March 20, 2022, between Reporting Owner and Issuer, remains in force and effect.
F2 This Option was issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer from February 1, 2022, through January 31, 2023.

Remarks:

This transaction was disclosed by the Issuer on Form 8-K filed with the SEC on March 24, 2022.